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Abstract
Background: The airway functions are profoundly affected in many diseases including asthma,
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). CF the most common
lethal autosomal recessive genetic disease is caused by mutations of the CFTR gene, which normally
encodes a multifunctional and integral membrane protein, the CF transmembrane conductance
regulator (CFTR) expressed in airway epithelial cells.
Methods: To demonstrate that CFTR is also expressed in tracheal smooth muscle cells (TSMC),
we used iodide efflux assay to analyse the chloride transports in organ culture of rat TSMC,
immunofluorescence study to localize CFTR proteins and isometric contraction measurement on
isolated tracheal rings to observe the implication of CFTR in the bronchodilation.
Results: We characterized three different pathways stimulated by the cAMP agonist forskolin and
the isoflavone agent genistein, by the calcium ionophore A23187 and by hypo-osmotic challenge.
The pharmacology of the cAMP-dependent iodide efflux was investigated in detail. We
demonstrated in rat TSMC that it is remarkably similar to that of the epithelial CFTR, both for
activation (using three benzo [c]quinolizinium derivatives) and for inhibition (glibenclamide, DPC
and CFTRinh-172). Using rat tracheal rings, we observed that the activation of CFTR by
benzoquinolizinium derivatives in TSMC leads to CFTRinh-172-sensitive bronchodilation after
constriction with carbachol. An immunolocalisation study confirmed expression of CFTR in
tracheal myocytes.
Conclusion: Altogether, these observations revealed that CFTR in the airways of rat is expressed
not only in the epithelial cells but also in tracheal smooth muscle cells leading to the hypothesis that
this ionic channel could contribute to bronchodilation.
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Background
The balance between constrictor and relaxant stimuli
influences the contractile state of the airway smooth mus-
cle cell (SMC). In order to be able to propose novel thera-
peutic agents for the treatment of airway obstruction
associated with several diseases such as asthma, chronic
obstructive pulmonary disease (COPD) and cystic fibrosis
(CF), it is important to understand the mechanisms
underlying control of the bronchoconstriction and dilata-
tion. Ion channels in epithelial, glandular and smooth
muscle cells are of fundamental importance in regulating
airway functions. Voltage-dependent cation (calcium and
potassium) channels have been studied in airway SMC
playing a role in excitation-contraction coupling [1].
Recently, the transient receptor potential (TRP) 6 channel
has been identified in rabbit portal vein smooth muscle
[2]. Different types of K+ and non-selective cation chan-
nels are also present in airway SMC but their molecular
entity as well as their physiological role on airway excita-
bility and function have not been clearly established [3,4].
On the contrary, relatively little work has been carried out
on the Cl-channels present in airway SMC. However,
depolarizing Calcium/Calmodulin Dependent Protein
Kinase II (CaMKII)-phosphorylated calcium-activated Cl-
currents coupled to intracellular calcium release have
been identified in tracheal myocytes [5].
Cystic fibrosis, the most common lethal autosomal reces-
sive genetic disease, is caused by mutations of the CF gene,
which normally encodes the CF transmembrane conduct-
ance regulator (CFTR), a multifunctional cAMP-depend-
ent Cl-  channel in the apical membrane of secretory
epithelial cells [6]. In CF, defective function of CFTR in
airway epithelial cells and submucosal glands results in
chronic involvement of the respiratory tract, manifested
by progressive airway obstruction that begins early in life.
Failure of Cl- secretion through CFTR or associated ion
channels results in the deshydration of endobronchial
secretions. Dessicated secretions block the airways and
prevent elimination of bacteria [7]. Bronchial hyper-reac-
tivity is a common problem in CF, occurring in as many
as 40% of affected individuals, which further contributes
to the airway obstruction [8]. A recent study suggests pos-
sible role for Cl- pathways in the modulation of airway
smooth muscle function and implications for fundamen-
tal studies of airway function as well as therapeutic
approaches to pulmonary disease [9].
Whereas CFTR has been generally regarded as specifically
expressed in epithelial cells [6], evidence for its expression
and/or function as a Cl- conductance has been obtained in
cardiac muscle cells [10,11], brain [12], endothelia
[13,14] and more recently in aortic SMC [15,16]. In this
study, we now present evidence that CFTR is also
expressed in tracheal smooth muscle cells (TSMC).
Exploiting new pharmacological tools (CFTR activators
and inhibitors) we also provided evidence for its contribu-
tion to the bronchodilation.
Methods
Tissue preparation
Wistar male rats (250–300 g) were stunned and then
killed by cervical dislocation according to the animal care
and use local committee. Trachea were removed and
placed into Krebs solution containing (in mM): 120 NaCl,
4.7 KCl, 2.5 CaCl2, 1.2 MgCl2, 1.2 KH2PO4, 15 NaHCO3,
11.1 D-glucose, pH 7.4.
Cell culture
The entire trachea preparation was rapidly removed and
rinced in culture medium (DMEM-HEPES supplemented
with 1 % penicillin-streptomycin, 1 % Na pyruvate, 1 %
non essential amino acids). Smooth muscle part of the
trachea was dissected under sterile conditions in culture
medium and was cut in several pieces (1–2 mm2).
Smooth muscle pieces were placed at the bottom of indi-
vidual wells of 6-well culture plates containing culture
medium enriched with 10 % foetal calf serum (FCS).
Organ culture plates were placed in a humidified incuba-
tor at 37°C under 5% CO2  in air. The medium was
changed every 48 h. After one week, confluent cells were
rinsed twice with Hanks' balanced salt solution and then
passaged with trypsin-EDTA. Isolated cells were then
seeded in a 24-well culture plate for functional study of
chloride channels activity. Cells were left in culture
medium for 48 h before they were growth arrested using
serum-free culture medium supplemented with 1% insu-
lin-transferrin-selenium (ITS) (as previously described)
[17].
Immunofluorescence study
Cells grown on glass coverslips were washed 3 times in
Tris-buffered saline (TBS) and after fixation, non specific
binding sites were blocked with TBS containing 0.5% BSA
and 0.05% saponin for 1 h. Cells were incubated with an
anti-CFTR C-terminal monoclonal antibody (1:100, Ig2a,
mouse anti-human, R&D Systems, Minneapolis, MN,
USA) or with monoclonal anti-alpha smooth muscle actin
(1:200, IgG2a Cy3 conjugate, Sigma Chemicals, St Louis,
MO, USA) for 2 h at room temperature. After 3 washes,
cells were incubated with the FluoProbes 488 (1:400,
Interchim, Montluçon, France) secondary antibody. In
the control, the primary antibody was omitted. Nuclei
were stained in blue with TO-PRO-3 iodide (Molecular
Probes, Eugene, OR) for 15 min at room temperature
(1:1000 in TBS). Fluorescence was examined with a spec-
tral confocal station FV 1000 installed on an inverted
microscope IX-81 (Olympus, Tokyo, Japan).Respiratory Research 2006, 7:113 http://respiratory-research.com/content/7/1/113
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Iodide efflux
CFTR Cl- channel activity was assayed by measuring the
rate of iodide (125I) efflux from cells as previously
described [18]. All experiments were performed with a
MultiPROBE®IIex robotic liquid handling system (Perkin
Elmer Life Sciences, Courtaboeuf, France). At the begin-
ning of each experiment, cells were washed twice with
efflux buffer containing (in mM) 136.9 NaCl, 5.4 KCl, 0.3
KH2PO4, 0.3 NaH2PO4, 1.3 CaCl2, 0.5 MgCl2, 0.4 MgSO4,
5.6 glucose and 10 HEPES, pH 7.4. Cells were incubated
in efflux buffer containing Na125I (1 µCi Na125I/ml, NEN,
Boston, MA) during 1 h at 37°C. Cells were then washed
with efflux medium to remove extracellular125I. The loss
of intracellular125I was determined by removing the
medium with efflux buffer every 1 min for up to 10 min.
The first three aliquots were used to establish a stable
baseline in efflux buffer alone. A medium containing the
appropriate drug was used for the remaining aliquots.
Residual radioactivity was extracted with 0.1 N NaOH/
0.1% SDS, and determined using a Packard Cobra™II
gamma counter (Perkin Elmer life Sciences, Courtaboeuf,
France). The fraction of initial intracellular125I lost during
each time point was collected and time-dependent rates
of125I efflux calculated from: ln (125It1 /125It2)/(t1 – t2)
where125It is the intracellular125I at time t, and t1 and t2
successive time points [18]. Curves were constructed by
plotting rate of125I versus time. All comparisons were
based on maximal values for the time-dependent rates (k
= peak rates, min-1) excluding the points used to establish
the baseline (k peak-k basal, min-1) [18]. All inhibitors
were pre-incubated 30 min.
Contraction measurement on isolated tracheal rings
After separation of connective tissues, the trachea was cut
into rings of 3 mm length. Tracheas were mounted
between a fixed clamp at the base of a water-jacketed 5 ml
organ bath containing an oxygenated (95% O2 and 5%
CO2) Krebs solution and an IT1-25 isometric force trans-
ducer (Emka Technologies, Paris, France) [15,16]. All
experiments were performed at 37°C. A basal tension of 2
g was applied in all experiments. During 1 h, tissues were
rinsed three times in Krebs solution and the basal tone
was always monitored and adjusted to 2 g. 1 µM Carba-
chol (CCH) were used to evoke the sustained contractile
response. Once the sustained tension was established, the
tissues were allowed to equilibrate further for 30 min
before cumulative addition of agonist to the bath. Cumu-
lative concentration-response relationships for the relax-
ant effect of MPB compounds were determined in trachea
rings following stable contraction. The relaxant effect of
CFTR agonists was expressed as percentage contraction of
the agonist-constricted tracheal rings. IC50 was calculated
as the drug concentration inducing a half-maximal dilata-
tion (or inhibition of contraction).
Statistics
Results are expressed as means ± SEM of n observations.
Sets of data were compared with analysis of variance
(ANOVA) or a Student's t test. Differences were consid-
ered statistically significant when P < 0.05. ns: non signif-
icant difference, * P < 0.05, ** P < 0.01, *** P < 0.001. All
statistical tests were performed using GraphPad Prism ver-
sion 4.0 for Windows (Graphpad Software, San Diego,
CA) and Origin version 5.0 (Rockware, Golden, CO).
Drugs and chemical reagents
The benzo [c]quinolizinium compounds 10-chloro-6-
hydroxybenzo [c]quinolizinium chloride (MPB-07), 5-
butyl-10-chloro-6-hydroxybenzo [c]quinolizinium chlo-
ride (MPB-91) and 10-fluoro-6-hydroxybenzo [c]quino-
lizinium chloride (MPB-80) were prepared as described
previously [19]. Carbamylcholine, glibenclamide, Insulin
– Transferrin – Selenium (ITS), monoclonal antibody
anti-α-smooth muscle actin, Na pyruvate, non essential
amino acids were purchased from Sigma Chemicals (Saint
Quentin Fallavier, France). DMEM-HEPES, Foetal Calf
Serum (FCS), Penicillin-Streptomycin, trypsin-EDTA and
Hanks' balanced salt solution were purchased from Gibco
(Invitrogen Corporation, Cergy Pontoise, France).
CFTRinh-172 was purchased from Calbiochem (USA). All
drugs were prepared in dimethyl sulfoxide (DMSO)
except MPB-07, MPB-80 and carbachol that were prepared
as stock solution in distilled water. The maximal concen-
tration of DMSO used in experiments was 0.1 % for glib-
enclamide and 0.3 % for MPB-91 and had no effect on
mechanical activity of the rings.
Results
Analysis of chloride transports in organ culture of rat 
TSMC
Immunostaining with the monoclonal anti-α-smooth
muscle actin antibody was positive (Fig. 1A) for all cells
demonstrating the presence of an homogenous popula-
tion of smooth muscle cells. The cells were positive for the
contractile phenotype. No staining was detected when the
anti-α-smooth muscle actin antibody was omitted (data
not shown). To investigate the Cl- transports is tracheal
smooth muscle cells, we prepared organ culture of rat tra-
cheal smooth muscle cells (TSMC). We began our study
by examining three different pathways for Cl- channels
stimulation, i.e. cAMP-, Ca2+- and volume-dependent
pathways. Transport properties of rat TSMC were studied
using the iodide efflux method allowing rapid and effi-
cient Cl- transport investigation [15,16], stimulated in
response to cell exposure to the cAMP-agonist forskolin
with the isoflavone genistein, to the Ca2+  ionophore
A23187 and to hypo-osmotic bath solution. No signifi-
cant iodide efflux was measured in resting TSMC (Fig. 1B,
open squares noted basal). However, a significant stimu-
lation (P < 0.001) of iodide efflux by the hypo-osmoticRespiratory Research 2006, 7:113 http://respiratory-research.com/content/7/1/113
Page 4 of 10
(page number not for citation purposes)
Analysis of chloride transports in rat airway smooth muscle cells Figure 1
Analysis of chloride transports in rat airway smooth muscle cells. A Immunofluorescence study of α-smooth muscle 
actin in tracheal smooth muscle cells from rat and B in the absence of primary antibody. Scale bars are 10 µm. C The stimula-
tion of iodide efflux as a function of time was evoked by an hypo-osmotic challenge, 1 µM A23187 and cAMP agonists (10 µM 
forskolin + 30 µM genistein) in rat airway smooth muscle cells as compared to basal. D Summary of the relative rates pre-
sented as mean ± S.E.M. Basal was vehicle alone.
0 2 4 6 8
0.0
0.1
0.2
0.3
basal
hypo-osmotic
A23187
Fsk + Gst
time (min)
k
 
(
m
i
n
-
1
)
hypo-osmotic
A23187
Fsk/Gst
basal
0.00
0.05
0.10
0.15
0.20 ***
***
***
k
p
e
a
k
-
k
b
a
s
a
l
 
(
m
i
n
-
1
)
A
B
CRespiratory Research 2006, 7:113 http://respiratory-research.com/content/7/1/113
Page 5 of 10
(page number not for citation purposes)
challenge (n = 4), A23187 (1 µM, n = 4) and cAMP agents
(10  µM forskolin with 30 µM genistein, n = 4) was
obtained as compared to resting TSMC cells (n = 4) (Fig.
1C). The response of cells to hypo-osmotic solution and
A23187 was faster and more pronounced than that of for-
skolin/genistein (Fig. 1C). This first set of results shows
multiple Cl- transports stimulated by hypo-osmotic chal-
lenge, cAMP and Ca2+ agonists in rat TSMC.
Does CFTR underlie the cAMP-dependent chloride 
transport in rat TSMC?
We then decided to focus our study on the cAMP-depend-
ent Cl- transport because it has never been described in
tracheal smooth muscle. It is known from numerous stud-
ies that in epithelial cells, the main Cl- channel underlying
cAMP-dependent Cl- transport is the CFTR Cl- channel [6-
9]. In the next series of experiments we hypothesized that
CFTR is present and functional in TSMC by using the cock-
tail forskolin/genistein (Fig. 2A). To test this hypothesis,
we first used different classes of Cl- channels inhibitors to
characterize the cAMP-dependent Cl-  transport in this
preparation. Glibenclamide and diphenylamine-2-car-
boxylic acid (DPC) are two non-specific inhibitors of Cl-
channels including CFTR [16,20,21], the stilbene deriva-
tive DIDS is a general blocker of Cl- channels but does not
inhibit CFTR from the extracellular [16,20,21] and TS-TM
calix [4]arene is an inhibitor of outwardly rectifying Cl-
channels but not of CFTR [16,21,22]. We observed that
100 µM glibenclamide or 500 µM DPC fully inhibited the
stimulation of iodide efflux with forskolin/genistein
while neither 100 nM calixarene nor 500 µM DIDS have
an inhibitory effect (Fig. 2B, n = 4 for each). To confirm
this pharmacological profile of inhibition, we tested the
thiazolidinone compound CFTRinh-172 which has been
recently developed as a specific CFTR blocker with no sig-
nificant inhibitory action on other Cl- channels, and espe-
cially on the volume- and calcium-activated Cl- channels
[23]. We compared the iodide efflux response of rat TSMC
to the cocktail forskolin/genistein in the presence or
absence of CFTRinh-172 used at 10 µM. It is clear from the
results presented in Fig. 2A and 2B, that the compound
fully inhibited the efflux demonstrating that CFTR is likely
to be responsible for most of the cAMP-regulated Cl- trans-
port in TSMC. This profile of inhibition is thus in perfect
agreement with that determined for CFTR in epithelial
[20,21] and aortic vascular smooth muscle cells [15,16]
and further supports our hypothesis that CFTR is present,
functional and cAMP-regulated in tracheal myocytes. To
study the presence of CFTR in rat TSMC, CFTR localization
was performed by indirect immunofluorescence confocal
microscopy. By using anti-CFTR C-terminal monoclonal
antibody, CFTR protein was detected in the plasma mem-
brane and within cytoplasmic compartments of rat TSMC
(Fig. 2C). No staining was detected when the primary
antibody was omitted (data not shown).
Pharmacological activation of CFTR channels in rat 
TSMC
If CFTR in TSMC and in epithelial cells are similar, then
we should observe its stimulation using known pharma-
cological activators of the epithelial CFTR, such as the
benzo [c]quinolizinium derivatives MPB-07 and MPB-91
[15,16,19,24]. A third drug within this chemical family,
MPB-80, not able to stimulate CFTR channel activity
[15,19] was also used here. MPB-07 and MPB-91 (250
µM, n = 4, Fig. 3A, B) stimulated iodide efflux from rat
TSMC but no stimulation was observed with MPB-80
(250 µM, n = 4, Fig. 3A, B). Like with the agonists forsko-
lin/genistein, the iodide efflux stimulated by MPB-91 was
insensitive to 100 nM calixarene, 500 µM DIDS but fully
inhibited in the presence of 100 µM glibenclamide, 500
µM DPC and 10 µM CFTRinh-172 (Fig. 3C, D). Therefore,
given the pharmacological profile of activation using
either forskolin/genistein or the benzo [c]quinolizinium
CFTR activators (MPB-91>MPB-07) and the fact that the
inactive compound MPB-80, like for the epithelial and
aortic CFTR [15,19], is not able to stimulate iodide efflux
in TSMC, these results demonstrate that CFTR in TSMC
shares numerous pharmacological properties with that
determined for epithelial and aortic CFTR [15,16,20,21].
Role of CFTR in agonist-dependent bronchodilation of 
smooth muscle cells
In the last part of our study, we performed experiments on
rat tracheal rings mounted in an organ bath apparatus and
measured their muscular activity. Initial experiments were
carried out to evaluate the contractile response to carba-
chol (CCH). We obtained a concentration-response curve
for CCH used between 10-7 to 10-3 M and determined a
half maximal response EC50 of 10-6 M (n = 8). This con-
centration of CCH was then used in the next experiments
described below. The CCH-induced constriction reached a
maximum, indicated by a plateau phase, and then
declined slowly during 4 h. The vehicle DMSO (used at
maximum 0.1%) had no effect on the maximum response
(data not shown). We applied the benzoquinolizinium
CFTR activators MPB-91, MPB-07 and the inactive ana-
logue MPB-80 via cumulative application into the organ
bath (3–200 µM). Clearly, MPB-91 induced a concentra-
tion-dependent relaxation of rat tracheal ring precon-
stricted by 1 µM CCH (Fig. 4A) that began at 10 µM and
was complete for 200 µM. From 13 different tracheal rings
we determined half-maximal relaxation value IC50 for the
CFTR activators MPB-91; IC50 of 42 ± 5 µM (n = 13) (Fig.
4B). Very similar results were obtained with the other
CFTR activator, MPB-07 (Fig. 4C) (IC50 of 94 ± 4 µM, n =
16) (Fig. 4D). Pre-incubation of NG-nitro-L-arginine
methyl ester (L-NAME), an inhibitor of nitric oxide syn-
thase (NOS), occurred before MPB07 exposure in con-
stricted airway segments from rat (Fig 4D) has no
significant effect on relaxation. This result suggests an epi-Respiratory Research 2006, 7:113 http://respiratory-research.com/content/7/1/113
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Pharmacological inhibition and immunolocalisation of CFTR in rat tracheal smooth muscle cells Figure 2
Pharmacological inhibition and immunolocalisation of CFTR in rat tracheal smooth muscle cells. A Iodide efflux 
response as a function of time evoked by cAMP agonists (10 µM forskolin + 30 µM genistein) and 10 µM CFTRinh-172. B Effect 
of 100 µM glibenclamide, 500 µM DPC, 500 µM DIDS, 100 nM calixarene and 10 µM CFTRinh-172 on the efflux stimulated by 
cAMP agonists in rat tracheal smooth muscle cells as indicated. Basal was vehicle alone. Data are presented as mean ± S.E.M. 
All experimental conditions have been repeated: n = 4. C Immunofluorescence study of CFTR in TSMC and D in the absence 
of primary antibody. α-smooth muscle actin is stained in red, CFTR in green and nucleus (TOPRO-3 staining) in blue. Scale bars 
are 10 µm.
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thelium-independent relaxation of rat TSMC. A very dif-
ferent effect was obtained with MPB-80 (the inactive
analogue of MPB-91). Indeed with MPB-80 a small relax-
ant effect was only seen above 60 µM (Fig. 4E). Using 8
different tracheal rings we failed to relax more than 50%
of the initial constriction induced by 1 µM CCH. Because
complete relaxation was not obtained we did not calculate
IC50 value (Fig. 4F, n = 8 for each concentration). To estab-
lish the implication in MPB-dependent bronchodilation,
we evaluated the effect of the specific CFTR inhibitor
CFTRinh-172 as antagonist of MPB-91. Fig. 4B shows that
in the presence of 10 µM and 100 µM CFTRinh-172 the
concentration response of MPB-91 shifted to the right
indicating concentration-dependent inhibition of
CFTRinh-172. Surprisingly, we observed that the response
induced by MPB-80 (Fig 4E) was similar to the response
observed after inhibition of CFTR activity using 100 µM
CFTRinh-172 in presence of MPB-91 (Fig 4B), a concentra-
tion which fully inhibited the CFTR activity (see effect of
10  µM CFTRinh-172 on efflux Fig 2B and 3D). These
results suggest that the relaxation induced by MPB-80 cor-
respond to a CFTR-independent effect on rat TSMC.
Discussion
The present study demonstrates for the first time that rat
tracheal smooth cells express CFTR chloride channel and
that its activation leads to a CFTRinh-172 dependent bron-
chodilation after muscarinic contraction. Based on our
experiments, a number of important findings could be
summarized as follow:
Pharmacological activation of CFTR chloride channels activity in rat airway smooth muscle cells Figure 3
Pharmacological activation of CFTR chloride channels activity in rat airway smooth muscle cells. A Iodide efflux 
responses as a function of time evoked by 250 µM MPB-07, MPB-91 and MPB-80. All experimental conditions have been 
repeated: n = 4. Basal was vehicle alone. B Summary of the data for each experimental condition after stimulation by MPB-07, 
MPB-80, MPB-91. C Iodide efflux response as a function of time evoked by MPB-91 (250 µM) and 10 µM CFTRinh-172. D Effect 
of 100 µM glibenclamide, 500 µM DPC, 500 µM DIDS, 100 nM calixarene and 10 µM CFTRinh-172 on the efflux stimulated by 
MPB-91 (250 µM) in rat tracheal smooth muscle cells as indicated. Basal was vehicle alone. Data are presented as mean ± 
S.E.M. All experimental conditions have been repeated: n = 4. *** P < 0.001, * P < 0.05. ns: non-significant difference.
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Bronchodilation effect of CFTR activators on rat trachea Figure 4
Bronchodilation effect of CFTR activators on rat trachea. Typical traces from experiments performed with tracheal 
rings preconstricted with 1 µM CCH. A The effect on tension of various concentrations of MPB-91. B Concentration-depend-
ent curves are displayed, showing the bronchodilation of tracheal rings preconstricted by 1 µM CCH for MPB-91 in absence 
(IC50 = 42 ± 5 µM, n = 13) or in presence of 10 µM CFTRinh-172 (IC50 = 71 ± 3 µM, n = 6), or 100 µM CFTRinh-172 (IC50 > 150 
µM, n = 7). C The effect on tension of various concentration of MPB-07. D Concentration-dependent curves showing the 
bronchodilation of tracheal rings preconstricted by 1 µM CCh for MPB-07 in absence (IC50 = 94 ± 4 µM, n = 16) or presence 
(IC50 = 87 ± 5 µM, n = 15) of 100 µM L-NAME (pre-incubated 30 min). E The effect on tension of various concentrations of 
MPB-80. F Concentration-dependent curves are displayed, showing the bronchodilation of tracheal rings preconstricted by 1 
µM CCH for MPB-80 (IC50 = 135 ± 5 µM, n = 8).
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(i) three different Cl-  transports stimulated by cAMP,
intracellular calcium and cell volume are present in rat
TSMC in organ culture,
(ii) the activation by the pharmacological CFTR activators
MPB derivatives of the tracheal CFTR channel is remarka-
bly similar to that of the epithelial CFTR. Moreover, the
structural and pharmacological specificity of benzo
[c]quinolizinium agents (i.e. the different activity of MPB-
80, MPB-07 and MPB-91) are conserved for CFTR in epi-
thelia and TSMC,
(iii) the inhibitory profile (glibenclamide, DPC and
CFTRinh-172) of the tracheal CFTR channel activity is
identical to that of the epithelial CFTR suggesting that
CFTR is the major pathway for cAMP-regulated chloride
transport in TSMC,
(iv) finally, using isometric contraction measurement on
rat isolated tracheal rings, we found that the activation of
CFTR leads to bronchodilation with a concentration-
dependent inhibition by CFTRinh-172.
The airway is a complex system with more than 20 differ-
ent cell types, a smooth muscle layer surrounding an epi-
thelial layer facing the lumen. In this multicellular organ,
CFTR is functionally expressed both in epithelial [7] and
in smooth muscle cells (this study). However, the link
between CFTR-mediated ion transport and the lung phys-
iology has been the subject of intense debate and remains
poorly understood. The role of the airway epithelium in
modifying the contractility of the underlying smooth
muscle has been suggested but is not yet fully demon-
strated. For example, it has been suggested that the pri-
mary function of the epithelium is to provide a barrier of
protection between the airway smooth muscle and
inhaled irritants [25]. Other studies have demonstrated
that the epithelium can be an active source of mediators
that relax constricted airways [26-28]. Fortner et al. [9]
tested the hypothesis that the epithelium-dependent
relaxation to agonists, like substance P and ATP, depends
on the activity of chloride channels. They have shown a
possible role for chloride pathways in the modulation of
airway smooth muscle function using various chloride
channel inhibitors. This work has also demonstrated that
the relaxation to substance P and ATP persisted in the tra-
cheas from Cftr-/- mice, and that the magnitude of the
relaxation was not significantly different from that in the
wild-type animals. This indicated that CFTR function is
not required for airways relaxation to substance P and ATP
[9]. However, another study demonstrated that tracheas
from CF mice have impaired relaxation in response to
electrical field stimulation [29]. This effect appears to be
related to the lack of NO produced by CF respiratory epi-
thelium and is readily reversible with exogenous NO or L-
arginine [29]. This observation is consistent with other
findings showing decreased exhaled NO in patients with
CF [30-32] and a reduction in NOS expression in CF
murine and human airway epithelial cells [33].
Recent progress into the pharmacology of chloride chan-
nels provided interesting new tools to study the contribu-
tion of these transport proteins into organ physiology. We
took advantage of the specific CFTR inhibitor CFTRinh-172
[23] to monitor the muscular reactivity of isolated rat tra-
cheal rings. Using this agent we found two complemen-
tary effects. First, it fully inhibits the iodide efflux
stimulated by forskolin/genistein or MPB compounds,
indicating that CFTR is the major ionic channel responsi-
ble for the cAMP-regulated Cl- transport in TSMC. Second,
we found concentration-dependent inhibition by
CFTRinh-172 of the bronchodilation induced by the CFTR
activators MPB after muscarinic stimulation. This phar-
macological evidence is in favour of an unexpected role of
CFTR in bronchodilation. It is well known that airway
smooth muscle relaxation is brought about predomi-
nantly by stimulation of adenyl cyclase-coupled receptors
(e.g. β2-adrenoceptor) resulting in elevation of cell cyclic
adenosine monophosphate content. Importantly, this sig-
nalling pathway is central in activating CFTR-mediated
chloride transport in epithelial [7,21], aortic [15], and air-
way smooth muscle cells. Taken together these results illu-
minate a direct implication for CFTR in the
bronchodilation of the rat trachea.
In disorders of the conducting airways like asthma, COPD
and CF, understanding the molecular mechanisms con-
trolling the contractile state of the airway smooth muscle
cell may generate new therapeutic opportunities. In CF,
chronic endobronchial infection is a primary feature of
the pulmonary disease. In addition, defective function of
CFTR in airway epithelial cells and submucosal glands
results in chronic involvement of the respiratory tract,
manifested by progressive airway obstruction that begins
early in life [7,36]. Asthma pathogenesis is characterized
by progressive airway wall remodelling that includes, in
part, local inflammation and fibrosis as well as increased
airway smooth muscle mass [34]. Recently, Hays et al.
[35] demonstrated structural changes to airway smooth
muscle in CF. They shown increased smooth muscle con-
tent of the airway in subjects with CF compared to healthy
controls. This increase is due to smooth muscle cell hyper-
plasia without hypertrophy [35]. These findings imply
that smooth muscle cell proliferation is a characteristic of
airway remodelling in CF [35]. Also, in the lungs of Cftr
null mice, an alteration in airway neuroendocrine cell and
neural components has been proposed [37]. It is charac-
terized by a decreased density of airway smooth muscle
innervation, mass and neuromuscular junctions [37].
These observations could suggest that CFTR plays a role inRespiratory Research 2006, 7:113 http://respiratory-research.com/content/7/1/113
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the development of pulmonary neuroendocrine cell sys-
tem, lung innervation and airway smooth muscle.
Although further studies will be required, these numerous
informations, together with our finding of CFTR expres-
sion in airway smooth muscle, suggest that CFTR in the
airways may have complex functions depending on the
cell type in which it is functional as a chloride channel.
Nevertheless, with greater understanding of the molecular
mechanisms leading to the control of bronchodilation
and the identification of novel bronchodilators(e.g.
potent CFTR activators) we are likely to be able to develop
new therapeutics for individuals with airway disease.
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